What Was Albiglutide (Tanzeum)? Why It Was Discontinued

Direct Answer

Albiglutide, sold as Tanzeum in the US, was a once-weekly GLP-1 medication approved by the FDA on April 15, 2014, for type 2 diabetes. GlaxoSmithKline discontinued it in 2018, and it's no longer available or prescribed anywhere. Importantly, the discontinuation was for commercial reasons, not safety concerns, weak weight loss results, an inconvenient injection device requiring powder reconstitution, and strong competition from dulaglutide and semaglutide made it commercially unviable.

Why It Couldn't Compete

Albiglutide produced modest results, roughly 0.5 to 1.5 kg of weight loss, compared to the 5 to 15 kg seen with semaglutide. Its injection device also required manual powder reconstitution before each dose, a real, practical disadvantage compared to competitors' simpler, pre-filled pens. Combined, these real, practical shortcomings, not any safety failure, led directly to GSK pulling it from the market in 2018.

A Real, Genuinely Important Legacy Worth Knowing

Despite its commercial failure, albiglutide's real HARMONY Outcomes trial demonstrated a genuine 22% reduction in major adverse cardiovascular events in high-risk type 2 diabetes patients, one of the earliest GLP-1 medications to show this kind of real cardiovascular benefit. This helped establish the entire GLP-1 class as genuine cardiovascular medications, not just diabetes or weight-loss drugs, a foundation later medications like semaglutide built on directly, covered in more detail on our SELECT trial page.

Mechanism

Albiglutide used albumin fusion technology, chemically linking two copies of the GLP-1 peptide to human albumin, extending its half-life to roughly 5 days and enabling once-weekly dosing, similar in spirit to the extended-release approaches used by later medications.

Bottom Line

Albiglutide is a real, historically significant, but fully discontinued GLP-1 medication, no longer available anywhere. Its real legacy lives on through the cardiovascular-benefit evidence it helped establish, even though it couldn't commercially compete with the medications that came after it.

References

• PMC: Tanzeum (Albiglutide), A Once-Weekly GLP-1 Receptor Agonist
• HARMONY Outcomes Trial, published cardiovascular results
• PeptideDeck: Albiglutide GLP-1 Analog Guide (2026)

Related Resources

• The GLP-1 Medication Timeline: 2005 to 2026
• The SELECT Trial: How Semaglutide Earned Its Cardiovascular Approval

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication, past and present.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.